One such company that looks well positioned for a solid gain, but has been overlooked by investors lately, is VIVUS Inc. (VVUS). This Medical – Biomedical/Genetics stock has actually seen loss estimates narrow over the past month for …
A year ago, they were trading at $1.04. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS Keywords: Vivus, Earnings Report
VIVUS Inc. VVUS reported a loss of 6 cents per share in the third quarter ... In fact, so far this year, VIVUS shares have underperformed the industry. The stock declined 43.4% during the period, while the industry witnessed a gain of 3.1%.
where a car fire caused its surging stock to cool off considerably. Elsewhere Diet drug darling Vivus (NASDAQ:VVUS) surged 17.04% but Potbelly (NASDAQ:PBP), up 119.79% on Friday, had the final word. Today in economics, August …
VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which …
Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Thursday's session 2.95% lower at $127.24 with a total trading volume of 1.37 million shares. Over the last month and the previous three months, the …
A year ago, they were trading at $1.04. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VVUS at https://www.zacks.com/ap/VVUS